Morgan Stanley Reiterates Overweight Rating on BioNTech (BNTX): "timing of announcement likely driving weakness in stock"
Tweet Send to a Friend
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $134.00 price target on BioNTech (NASDAQ: BNTX)The analyst commented, "BNTX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
